RA-MAP: A Landmark Paper in the Immunological Mapping of Early Rheumatoid Arthritis.

This is an extraordinary paper.

https://www.nature.com/articles/s41597-022-01264-y 

Congratulations to everyone involved.  Not only is this an important study, but the way it was done, team science at its best with shared authorship, open data sharing to public data repositories, open code sharing in accordance with both the spirit of FAIR as well as the letter of FAIR principles.

Clinical Trajectories in Early Seropositive Rheumatoid Arthritis

Not all patients respond equally well to treatment.  Here is the link to the clinical trajectories paper identifying three distinct trajectories for early seropositive rheumatoid arthritis patients.

RA-MAP Consortium, 2021. Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study. Therapeutic advances in musculoskeletal disease, 13, p.1759720X211043977.  https://doi.org/10.1177/1759720X211043977

Mapping Rheumatoid Arthritis

Big day today.

The "RA-MAP Universe" will be unveiled for the first time at EULAR 2019 in Madrid.

The first complete network map of systems involved in early rheumatoid arthritis.

RA Predictors of Remission

And for those who missed it the first time around, here is the link to clinical trajectories paper.

RMD Open. 2018 Oct 25;4(2):e000721. doi: 10.1136/rmdopen-2018-000721. 

Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data.

https://www.ncbi.nlm.nih.gov/pubmed/30487994

Good News: RA-MAP joins IMID-Bio

As many will know the RA-MAP consortium has joined forces with other consortia to better understand immune-mediated inflammatory diseases.

The IMID-BIO project brings together a number of consortia from across the UK.

This is the future of open collaborative research in science.

We are excited about this!

You can read the latest newsletter here:

 https://twitter.com/imidbio/status/1019131476363956224

And follow us on twitter @imidbio